Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 36, 2022 - Issue 4
246
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Two new compounds with anti-inflammatory activity from Alangium chinense

, & ORCID Icon
Pages 891-895 | Received 22 Aug 2020, Accepted 24 Oct 2020, Published online: 04 Nov 2020
 

Abstract

A new phenolic glycoside, chinenside A (1), and a new megastigmane glycoside, chinenionside A (2), together with twelve known compounds (3-14), were isolated from the roots of Alangium chinense. Their structures were deduced on the basis of extensive spectroscopic analyses and comparison with data reported in the literature. The anti-inflammatory activity in vitro of all 13 phenolic glycosides was evaluated against lipopolysaccharide-induced mouse macrophage RAW264.7 cells. The compounds 1, 9, and 10 potentially inhibited the productions of nitric oxide (NO), prostaglandin (PEG2), tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β) and interleukin 6 (IL-6). Compound 1 (50 μM) showed stronger anti-inflammatory activity than Triptolide (TPL, 20 nm).

Graphical Abstract

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was financially supported by the National Science and Technology Major Project of china (No.2011ZX09102-004-02), the National Natural Science Foundation of China (No.81373917).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.